nach oben

Erschienen in:

02.02.2021 | Original Article

Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas

verfasst von: Ziren Kong, Yucheng Zhang, Delin Liu, Penghao Liu, Yixin Shi, Yaning Wang, Dachun Zhao, Xin Cheng, Yu Wang, Wenbin Ma

Erschienen in: Annals of Nuclear Medicine | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Isocitrate dehydrogenase (IDH) mutation, telomerase reverse transcriptase (TERT) promoter mutation and O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation status are diagnostic, prognostic, predictive and therapeutic biomarkers for primary diffuse gliomas, and this study aimed to explore the relationship between choline (CHO) positron emission tomography (PET) parameters and these molecular alterations.

Methods

Twenty-eight patients who were histopathologically diagnosed with primary diffuse glioma and underwent presurgical CHO PET/CT were retrospectively analyzed, and IDH, TERT and MGMT alterations were examined. The volume of interest (VOI) was semiautomatically defined based on standardized uptake value (SUV) thresholds, and 5 traditional CHO parameters, namely, SUVmax, SUVmean, metabolic tumor volume (MTV), total lesion CHO uptake (TLC) and tumor-to-normal contralateral cortex activity ratio (T/N ratio), were calculated. Wilcoxon rank-sum tests and receiver operating characteristic (ROC) curves were applied to evaluate the differences and performances of the CHO parameters, and their capability to stratify patient prognosis was also evaluated.

Results

All 5 parameters were significantly higher in IDH-wildtype gliomas than in IDH-mutant gliomas (p = 0.0001–0.037), and SUVmax, SUVmean, TLC and the T/N ratio exhibited good performances in distinguishing the IDH status (areas under the ROC curve (AUCs) 0.856–0.918, accuracies 0.857–0.893) as well as stratifying patient prognosis. Although the differences and performances of the traditional parameters in distinguishing diverse TERT and MGMT statuses were moderate in the whole population, the T/N ratio and TLC displayed certain predictive value in discriminating the TERT status in the IDH-mutant and IDH-wildtype subgroups (p = 0.028–0.048, AUCs 0.857–0.860, accuracies 0.800–0.917, respectively).

Conclusions

Traditional CHO PET parameters are capable of distinguishing IDH but not TERT or MGMT alterations in the whole population. In accordance with the clinical understanding of TERT promoter mutations, the T/N ratio and TLC can also discriminate the TERT status in IDH subgroups.

Nur mit Berechtigung zugänglich

Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432–46.PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.PubMedPubMedCentralCrossRef

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18:1529–37.PubMedPubMedCentral

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med. 2016;374:1344–55.PubMedPubMedCentralCrossRef

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefPubMed

Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. 2016;18:16–26.PubMedCrossRef

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.PubMedPubMedCentralCrossRef

Arita H, Narita Y, Takami H, Fukushima S, Matsushita Y, Yoshida A, et al. TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas. Acta Neuropathol. 2013;126:939–41.PubMedCrossRef

10.

Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.PubMedCrossRef

11.

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499–508.PubMedPubMedCentralCrossRef

12.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.CrossRefPubMed

13.

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016;4:79.PubMedPubMedCentralCrossRef

14.

Kim MM, Parolia A, Dunphy MP, Venneti S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol. 2016;13:725–39.PubMedPubMedCentralCrossRef

15.

Giovannini E, Lazzeri P, Milano A, Gaeta MC, Ciarmiello A. Clinical applications of choline PET/CT in brain tumors. Curr Pharm Des. 2015;21:121–7.PubMedCrossRef

16.

Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-¹¹C]choline. J Nucl Med. 1997;38:842–7.PubMed

17.

Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med. 2001;28:1664–70.PubMedCrossRef

18.

Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K. Comparison of ¹¹C-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging. 2004;31:1064–72.PubMed

19.

Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, et al. Metabolic assessment of gliomas using ¹¹C-methionine, [¹⁸F] fluorodeoxyglucose, and ¹¹C-choline positron-emission tomography. AJNR Am J Neuroradiol. 2008;29:1176–82.PubMedCrossRefPubMedCentral

20.

Garcia Vicente AM, Perez-Beteta J, Amo-Salas M, Pena Pardo FJ, Villena Martin M, Sandoval Valencia H, et al. ¹⁸F-Fluorocholine PET/CT in the prediction of molecular subtypes and prognosis for gliomas. Clin Nucl Med. 2019;44:e548–58.PubMedCrossRef

21.

Takei H, Shinoda J, Ikuta S, Maruyama T, Muragaki Y, Kawasaki T, et al. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. J Neurosurg. 2019;133:1010–9.CrossRef

22.

Hara T, Kosaka N, Kishi H. Development of ¹⁸F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187–99.PubMed

23.

Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68:1319–25.PubMedCrossRef

24.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Mod Pathol. 2015;28:177–86.PubMedCrossRef

25.

Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131:1342–50.PubMedCrossRef

26.

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30:1323–41.PubMedPubMedCentralCrossRef

27.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, et al. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol. 2016;18:1099–108.PubMedPubMedCentralCrossRef

28.

Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;2020:1903327.

29.

Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6:495–503.PubMedPubMedCentralCrossRef

30.

Kong Z, Jiang C, Zhang Y, Liu S, Liu D, Liu Z, et al. Thin-slice magnetic resonance imaging-based radiomics signature predicts chromosomal 1p/19q Co-deletion status in Grade II and III Gliomas. Front Neurol. 2020;11:551771.PubMedPubMedCentralCrossRef

31.

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126:267–76.PubMedCrossRef

32.

Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, et al. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Acta Neuropathol Commun. 2020;8:201.PubMedPubMedCentralCrossRef

33.

Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol. 2018;136:805–10.PubMedPubMedCentralCrossRef

34.

Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981–22981/CE3. Lancet Oncol. 2008;9:29–38.PubMedCrossRef

35.

van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881–6.PubMedPubMedCentralCrossRef

36.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645–53.PubMedPubMedCentralCrossRef

37.

Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, et al. Association of MGMT promoter methylation status with survival outcomes in patientswith high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424. JAMA Oncol. 2018;2018:5.

38.

Okita Y, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y, Mano M, et al. The association between ¹¹C-methionine uptake, IDH gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas. Clin Radiol. 2020;2020:5.

39.

Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y, et al. ¹⁸F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. Cancer Imaging. 2019;19:58.PubMedPubMedCentralCrossRef

40.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro Oncol. 2016;18:549–56.PubMedPubMedCentralCrossRef

41.

Duffau H, Taillandier L. New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach. Neuro Oncol. 2015;17:332–42.PubMedCrossRef

42.

Kong Z, Jiang C, Zhu R, Feng S, Wang Y, Li J, et al. ¹⁸F-FDG-PET-based radiomics features to distinguish primary central nervous system lymphoma from glioblastoma. Neuroimage Clin. 2019;23:101912.PubMedPubMedCentralCrossRef

43.

Ohno M, Narita Y. A case of glioblastoma invasion clearly demonstrated on 11C-methionine positron emission tomography. Jpn J Clin Oncol. 2013;43:448.PubMedCrossRef

44.

Yamauchi T, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, et al. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathol. 2018;35:148–58.PubMedCrossRef

45.

Tanaka K, Yamamoto Y, Maeda Y, Yamamoto H, Kudomi N, Kawai N, et al. Correlation of 4’-[methyl-¹¹C]-thiothymidine uptake with Ki-67 immunohistochemistry and tumor grade in patients with newly diagnosed gliomas in comparison with ¹¹C-methionine uptake. Ann Nucl Med. 2016;30:89–96.PubMedCrossRef

46.

Toriihara A, Ohtake M, Tateishi K, Hino-Shishikura A, Yoneyama T, Kitazume Y, et al. Prognostic implications of ⁶²Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET/CT in patients with glioma. Ann Nucl Med. 2018;32:264–71.PubMedCrossRef

Titel: Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas
verfasst von: Ziren Kong
Yucheng Zhang
Delin Liu
Penghao Liu
Yixin Shi
Yaning Wang
Dachun Zhao
Xin Cheng
Yu Wang
Wenbin Ma
Publikationsdatum: 02.02.2021
Verlag: Springer Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 4/2021
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01589-5

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT

High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients

Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer

Diagnostic value of [18F]Fluorocholine PET/CT in detection of primary medullary thyroid cancer

Prediction of local recurrence and distant metastasis using radiomics analysis of pretreatment nasopharyngeal [18F]FDG PET/CT images

A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography